Belite Bio 将来の成長

Future 基準チェック /56

Belite Bioは、69.4%と74.4%でそれぞれ年率69.4%で利益と収益が成長すると予測される一方、EPSはgrowで68.6%年率。

主要情報

69.4%

収益成長率

68.6%

EPS成長率

Pharmaceuticals 収益成長	23.9%
収益成長率	74.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	14 Nov 2024

今後の成長に関する最新情報

Recent updates

We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow

Sep 26

Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

Jul 03

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Mar 20

An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

Jan 10

Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

Jul 31

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

May 03

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Oct 03

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Jul 19

業績と収益の成長予測

NasdaqCM:BLTE - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	37	-20	-9	N/A	3
12/31/2025	10	-32	-36	N/A	5
12/31/2024	N/A	-36	N/A	N/A	5
9/30/2024	N/A	-33	N/A	N/A	N/A
6/30/2024	N/A	-35	N/A	N/A	N/A
3/31/2024	N/A	-33	N/A	N/A	N/A
12/31/2023	N/A	-32	-30	-30	N/A
9/30/2023	N/A	-31	N/A	N/A	N/A
6/30/2023	N/A	-23	N/A	N/A	N/A
3/31/2023	N/A	-18	N/A	N/A	N/A
12/31/2022	N/A	-13	-12	-11	N/A
9/30/2022	N/A	-8	N/A	N/A	N/A
6/30/2022	N/A	-8	N/A	N/A	N/A
3/31/2022	N/A	-8	N/A	N/A	N/A
12/31/2021	N/A	-10	-8	-7	N/A
9/30/2021	N/A	-9	N/A	N/A	N/A
6/30/2021	N/A	-8	-7	-7	N/A
3/31/2021	N/A	-7	-6	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BLTEは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: BLTE今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: BLTE今後 3 年以内に収益を上げることが予想されます。

収益対市場: BLTEの収益 ( 74.4% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: BLTEの収益 ( 74.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BLTEの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Belite Bio 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Price target increased by 18% to US$66.75

Price target decreased by 21% to US$45.67

Recent updates

Price target increased by 18% to US$66.75

Key Executive notifies of intention to sell stock

We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow

Director notifies of intention to sell stock

Belite Bio Announces Appointment of Hendrik P. N. Scholl as Chief Medical Officer

Key Executive notifies of intention to sell stock

Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

CFO & Director notifies of intention to sell stock

Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Belite Bio, Inc has filed a Follow-on Equity Offering in the amount of $24.999964 million.

Director notifies of intention to sell stock

Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Chief Scientific Officer notifies of intention to sell stock

An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

CFO & Director notifies of intention to sell stock

Director notifies of intention to sell stock

Key Executive notifies of intention to sell stock

Key Executive notifies of intention to sell stock

New minor risk - Shareholder dilution

Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

New major risk - Share price stability

Price target decreased by 21% to US$45.67

Belite Bio, Inc. Doses First Subject in Pivotal Phase 3 Phoenix Trial Evaluating Oral Tinlarebant for Ga

Belite Bio, Inc. Completes Enrollment in Pivotal Global Phase 3 Dragon Trial Evaluating Oral Tinlarebant for Stargardt Disease

Belite Bio, Inc to Report Q1, 2023 Results on May 10, 2023

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Belite Bio, Inc Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)

Less than half of directors are independent

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Belite Bio, Inc Presents 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease At AAO Annual Meeting 2022

Belite Bio Receives Approval of Lbs-008 Phase 3 Clinical Trial in China

Belite Bio receives approval of begin LBS-008 phase 3 trial in China

Belite Bio Initiates Pivotal Phase 3 Clinical Trial of Lbs-008 in Stargardt Disease in the U.S

Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.

Belite Bio GAAP EPS of -$0.23 beats by $0.05

Belite Bio, Inc to Report Q2, 2022 Results on Aug 10, 2022

Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

Belite Bio, Inc Submits Investigational New Drug Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Belite Bio, Inc Presents Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

Belite Bio Receives FDA Fast Track Designation For LBS-008

No independent directors

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘